Related Experiment Videos
Circadian pharmacokinetics of methotrexate
B A Robinson1, E J Begg, B M Colls
1Department of Clinical Oncology, Christchurch Hospital, New Zealand.
Cancer Chemotherapy and Pharmacology
|January 1, 1989
Abstract:
Six patients with intermediate- and high-grade non-Hodgkin's lymphoma were treated with 400 mg/m2 i.v. methotrexate (MTX) at 0600 and 1800 hours. Despite evidence of circadian rhythms in renal function, the pharmacokinetics of total and free serum MTX showed no significant difference between these two times. The marked two-fold circadian variation in MTX pharmacokinetics previously reported in rats was not observed in these patients.